Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of PsA as classified by CASPAR criteria for at least 6 months before randomization.
Active PsA at baseline defined as ≥ 3 tender joints out of 68 and ≥ 3 swollen joints out of 66 (dactylitis of a digit counts as one joint each).
Inadequate response or intolerance to previous or current treatment with at least one TNFα inhibitor
Inadequate response or intolerance to conventional disease modifying anti-rheumatic drugs (cDMARDs)
Diagnosis of active plaque psoriasis, with at least one psoriatic plaque of ≥ 2 cm diameter and/or nail changes consistent with psoriasis and/or documented history of plaque psoriasis.
Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibodies negative at screening.
You may not be if
Pregnant or nursing women,
Previous exposure to secukinumab, ustekinumab or any other biologic drug directly targeting IL-17, IL-17 receptor, IL-12 or IL-23.
Patients for whom the use of secukinumab or ustekinumab is contraindicated.
Use of any other investigational drug. Previous treatment with any cell-depleting therapies including but not limited to anti-CD20 or investigational agents
Evidence of ongoing infectious or malignant process
Subjects receiving high potency opioid analgesics
Ongoing use of prohibited psoriasis treatments/medications
